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4Foreword
Pfizer Healthcare Ireland
The statistics in relation to medication non-adherence make for stark reading.  
Non-adherence is costing EU governments an estimated €125 billion annually and 
contributing to the premature deaths of nearly 200,000 Europeans a year.31
Non-adherence can have a profound impact for patients as many will not achieve 
optimal management of their disease and may continue to experience complications or 
progression of their disease. It also has major cost implications as much expenditure is  
in effect being “wasted” on medicines that are not being taken at all or taken incorrectly. 
This report aims to provide an insight into the main drivers of, and barriers to, patient 
adherence in Ireland.  
The main reason for not taking medication was simple forgetfulness which was cited  
by 71% of those surveyed; followed by lack of belief that the medication was needed 
(20%) and the belief that the condition has improved and hence medication is not  
needed (16%). 
The reasons for non-adherence can be broadly divided into non-intentional (e.g. patient 
forgot or didn’t understand the dosing regimen) to intentional (e.g. didn’t feel medication 
was necessary; was worried about side effects; deliberate dose-stretching to reduce 
cost). Non-intentional non-adherence is likely to be easier to address through patient 
reminders and prompts whereas intentional non-adherence requires different strategies. 
In times of increased scrutiny of expenditure on medicines, it is important that all 
stakeholders involved, including healthcare professionals, pharmaceutical companies, 
patients and their families/carers and policy-makers look at strategies to improve 
adherence which will result in better health outcomes for patients and potentially  
reduced cost as disease and illness are better managed.
Mr Paul Reid
Managing Director, Pfizer Healthcare Ireland
5Irish Pharmacy Union
Non-adherence to medications undermines healthcare outcomes and also has a  
significant economic cost. With the growing emphasis in healthcare systems on  
securing maximum value from spending on medicines, it is imperative that patients  
take their medicines as directed.
While finance and health budgets are major concerns, the key beneficiaries of better 
medication adherence are the patients themselves. Adherence to medication results  
in better health outcomes for patients and in turn an improved quality of life. 
Pharmacists are among the most accessible and most consulted healthcare professionals 
and are therefore ideally placed to tackle non-adherence to medication, by educating 
patients, helping them make informed decisions about their medicines and supporting 
them in adhering to their prescribed therapy, thus ensuring that, by taking the right 
medicines in the right way at the right time, patients achieve optimum benefit.
Services to improve medication adherence have the potential to improve patients’ 
health and quality of life and reduce healthcare costs. The development of pharmacy-
based services including Medicine Use Reviews and New Medicine Services can improve 
healthcare outcomes and assist pharmacists in addressing patient non-adherence to 
medications. Medication reviews and adherence programmes are part of a wider trend 
internationally towards expanding the role of pharmacists, in order to improve patients’ 
treatment outcomes, improve their quality of life and save downstream healthcare costs.
This report takes a comprehensive look at the extent and problem of non-adherence 
to medication in Ireland. The barriers, including social, economic and psychological 
concerns, are outlined and key solutions are identified.
While the issues addressed in this report are challenging, there is no doubt that a 
concerted effort by all stakeholders, including patients, healthcare professionals, the 
pharmaceutical sector and all those involved in healthcare outcomes, can lead to an 
improvement in adherence levels.
Addressing patient non-adherence to medication is of crucial importance to everyone 
and this report will assist in raising the required awareness necessary to stimulate the 
development of a coherent strategy to address the barriers to adherence, and identify and 
implement tailored policies to ensure long-term compliance. 
Rory O’ Donnell MPSI
President, Irish Pharmacy Union
6Irish Patients’ Association
It is very likely that one of our generations’ strengths is that we spend a huge amount 
of our resources collectively and individually on our health, to solve health problems and 
protect or expand the spaciousness of our health versus all the previous generations 
known to us.
This report illustrates that patient non-adherence to medicine consumption remains 
a serious challenge. 18% of respondents in this survey who have a medical condition 
report to be non-compliant which means that, medicinally at least, their illness will not 
be managed adequately. In addition, they may become more physically and mentally 
dependant on family and other carers due to their deteriorating conditions, quality of 
life can be adversely affected, they may die prematurely and yes, because prescribed 
medicines were not taken appropriately, they may become a greater cost burden to the 
healthcare system, consuming resources that could be better spent on the needs of others. 
According to a recent study* the consequences of non-adherence not only includes 
suboptimal clinical outcomes but also avoidable healthcare expenditure. The study 
demonstrated that each dollar spent on adherence support towards prescribed medicines 
would reduce overall medical costs by $7 for diabetic patients, $5 for hypercholesterolaemic 
patients, and $4 for hypertensive patients. As a result, it has been argued that “increasing 
the effectiveness of adherence interventions may have a far greater impact on the health of 
the population than any improvement in specific medical treatments”. 
This report marks another step forward in patient safety through creating awareness of 
the extent and level of non-adherence in the Ireland. 
The report and analysis importantly recommend various strategies to assist patients move 
from being “not always/never” compliant to always taking their medicines as prescribed 
for their benefit. It suggests a holistic system wide approach to empower patients to 
accept responsibility and take their medicines appropriately. All relevant stakeholders in 
patient well-being i.e. the family doctor, the pharmacist, the payer, the policy maker and 
manufacturer should play a role in promoting the importance of adhering to prescribed 
medication at every opportunity with the patient. As the message of “Have you washed 
your hands?” is so important to combat spread of infection, “Are you taking you 
medicine?” is equally important to support adherence. 
Recent research from Dublin City University, “Informing Irish Patients”, commissioned by 
the IPA and funded by the then HIQA interim board, reiterated that “patients should take 
seriously their responsibility to inform themselves about their health their medications and 
any other treatments they might be receiving”.
As a patient advocate with a passion for embedding a culture of patient safety everywhere, 
my call to action for patients is: Take your medicines as prescribed! And to health 
professionals; Always ask your patients “Have you taken your medicine as instructed?” 
Stephen McMahon,
CEO Irish Patients’ Association
*  Nihar R. Desai, Niteesh K. Choudhry. Impediments to Adherence to Post Myocardial Infarction Medications.  
Curr Cardiol Rep (2013) 15:322.
7Executive Summary
This report reviews the existing literature on medication adherence and outlines results from  
a survey examining adherence in Ireland and the factors which hinder/promote it.
•  Ensuring that patients take their medications as prescribed is an increasingly important aspect  
to effective management
•  The World Health Organisation (WHO) reports that when long-term medication is prescribed, 
approximately 50% of patients fail to adhere to the prescribed regimen1
•  It is estimated that 20% to 30% of patients do not adhere to medication regimens that are 
curative or relieve symptoms, and 30% to 40% fail to follow regimens designed to prevent  
health problems2
•  Existing literature further confirms that patients find it difficult to adhere to their medication 
regimens when suffering from multiple conditions
•  Non-adherence to medications can have a negative impact on the efficacy of treatments, patient 
well-being and the use of healthcare resources1,16-19
•  Patient non-adherence leads to significant costs for healthcare systems16,24-25
•  Medication non-adherence is costing EU governments an estimated €125 billion and contributing 
to the premature deaths of nearly 200,000 Europeans annually31
•  The Irish Platform for Patients’ Organisations, Science and Industry (IPPOSI) has identified 
patient non-compliance and non-adherence as an important issue to highlight, discuss and tackle2
•  IPPOSI has identified poor medication and treatment compliance as a significant issue within the 
Irish health system, which affects patient outcomes and costs for the health service2
•  IPPOSI stated that specific and detailed Irish research was needed to examine the issues behind 
compliance failure across preventative, chronic and acute treatment2
•  There are a wide variety of factors which determine patients’ adherence. They can be generally 
categorised as follows:1,3
•  Patient-related factors
•  Healthcare system and provider-related factors
•  Treatment-related factors
•  Condition-related factors
•  Cost-related factors
• Socio-economic & demographic factors
8Survey findings 
•  The study included a nationally representative sample of 1,003 adults aged 16 and over, of whom 
283 were suffering from one of a number of significant conditions
•  The Irish survey examined adherence using a number of different questions. When asked whether 
they always take their medication without fail, 18% reported they were not fully adherent all of 
the time (Figure 3)
•  In the demographic sub-analysis, 23% of men and 23% of individuals aged ≤35 yrs tended to 
miss their medication doses at least once a month (Figure 3)
•  Of the conditions requiring regular medication, patients with asthma, diabetes and high 
cholesterol reported lowest levels of adherence (30% in people with high cholesterol and 31% in 
people with asthma and diabetes) (Figure 4)
•  Of those who sometimes miss their medication, 64% missed it one or more times a week (Figure 6)
•  When asked about adherence in general, 29% of subjects surveyed stated that they didn’t 
remember to take their medication (Figure 11). When carers were asked about the management 
of individuals under their care, 52% said that the person they care for regularly forgets to take 
their medication (Figure 10)
•  The most common reason for missing medications was simple forgetfulness (71% of all 
respondents). Other reasons included patient perception that they don’t need the medication 
anymore (20%); they feel better (16%); they were anxious about the side effects (5%) or they 
didn’t believe that the medication was effective (4%) (Figure 12)
•  Amongst the non-adherent patients, the most common barriers to adherence were the perception 
that the medication/treatment does not make a difference (44%) or the perception that their 
treatment will not prevent further deterioration of their condition (39%) (Figure 11). Both these 
barriers can be addressed by appropriate patient education
•  The three factors ranked most important in ensuring people take their medication as prescribed 
was talking regularly to the doctor (74%); having a good understanding of the illness (42%); and 
having a good understanding of the medication (40%) (Figure 13) 
•  27% of the adult population surveyed had a listed medical condition (Figure 1)
•  Of those with a listed condition, 40% had more than one condition; amongst those who were  
≥65 yrs of age, 53% suffered from multiple conditions (Table 1)
•  Likelihood of non-adherence increased with increasing number of conditions the patient  
suffered from
•  Approximately 43% of patients had a review with a healthcare professional in the past month. 
The likelihood of recent reviews (within the last month) was associated with patients on medical 
cards vs. those who were self-funded or on other healthcare schemes (59% vs. 38% and 43%, 
respectively) (Figure 7a)
•  Patients who were reviewed by a healthcare professional regularly tended to be more adherent to 
their treatment than patients who had longer time intervals between reviews (Figure 8)
9•  Patient counselling and education have previously been shown to improve adherence3,4,5,6,7 and 
indeed, in this survey, patients who had a better understanding of their illness and associated 
treatment as well as more recent visits to a healthcare professional, demonstrated higher 
adherence rates than their counterparts (Figure 14)
•  Chronic pain was reported as the most frequently reviewed condition by a doctor in the past 
month (Figure 7b)
•  Almost 80% of all patients perceived their medication as effective (Figure 15)
•  A majority of all patients (76%) claimed to have no formal method or system to help monitor the 
usage of their medications (Figure 18)
•  Of the 24% of patients who did use an intervention/assistance method to help remember their 
medication; most used a pillbox (20%) (Figure 18)
•  Those who self-funded their medication, patients ≤50 yrs of age and non-adherent patients were 
least likely to use any prompt to help them remember to take their medication (Figure 18)
Literature analysis
•  The literature search identified 47 articles and reports after applying the selection criteria
•  Generally there was a high degree of concordance between factors affecting adherence identified 
in this survey and the literature analysis
•  The adherence rate reported in Ireland was higher than that reported in other studies. In other 
studies, the average rate of adherence was up to 50%, whereas overall, across all demographics 
and conditions, 82% was reported in this survey. However, amongst specific sub-populations, the 
rate of non-adherence varied significantly between 23-52%
•  Intervention tools most commonly employed, which improved adherence, included improving 
patient education about the disease/treatment through digital channels (e-channels) or patient 
literature or simple discussions with the patient; monitoring patient adherence; using reminders; 
simplifying medication regimens or employing more convenient care methods
Key conclusions
•  Adherent patients tend to have regular contact with their healthcare professional
•  Regular review of patients and follow-up is essential and is the responsibility of the healthcare 
provider/management team, including pharmacists. However, it is possible that regular review 
might be required for some patient populations more than others and in some disease areas more 
than others
•  Older patients tend to have more regular contact with their doctor. There would appear to be a 
need to similarly motivate younger patients, possibly through digital channels, in order to prevent 
worsening of their conditions as they age
•  “Forgetfulness” was the main self-reported reason for patients missing their medication. This is in 
line with the World Health Organization’s (WHO) finding in its adherence report1 
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•  Significant unmet needs identified by the survey and supplemented by the literature analysis 
include:
•  Patient education regarding their condition and medication
•  Regular follow-up
•  Use of reminders/prompts to improve adherence
•  Simplification of regimens
•  The use of memory aids, watch alarms, calendar packs, pillboxes or specialised dose dispensers 
may be helpful tools to increase adherence to treatment in patients who regularly forget to take 
their medications1
•  Healthcare professionals play an important role in emphasising the importance of adherence at 
each visit
•  Patient-related requirements, which can be achieved through regular contact with doctors, 
pharmacists or nurses include: 
•  Need to understand the illness
•  Need to discuss concerns about medication with a healthcare professional
•  Need to understand how medication works
•  Need support from family/carer to help remember medication
•  Need support from pharmacists
•  Need other support to remember medication
•  Need practical advice on how to use devices correctly
•  Need support from patient groups
•  Doctors and pharmacists can take a very active and important role in promoting and maintaining 
patient adherence
•  Improving adherence can help save costs for the healthcare system overall. Payers can benefit 
greatly from improved adherence in terms of improved productivity of individuals over the longer 
term and reduced long-term care costs as disease progression is slowed and patients experience 
fewer complications and recurrent episodes
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Introduction1
Medication is often the first choice for medical intervention of chronic and most acute diseases. 
Ensuring that patients take their medications as prescribed is an increasingly important aspect to 
effective management. Adherence has been defined as the “active, voluntary, and collaborative 
involvement of the patient in a mutually acceptable course of behaviour to produce a therapeutic 
result”.8 The lack of adherence to prescribed therapies is termed “medication non-adherence.”
Approximately 91% of adults aged between 57-85 yrs and older take at least one prescription drug 
a day, and 29% take five or more medications on a regular basis.9 The issuing of a prescription is 
the first step towards safe and high-quality pharmacotherapy; however, in one study, 20% of breast 
cancer patients had stopped filling their prescription at one year; this rose to 50% at five years 
which would have had a significant impact on survival rates.2 The WHO reports that when long-
term medication is prescribed, 50% of patients fail to adhere to the prescribed regimen.1 Capgemini 
Consulting carried out a survey in order to examine adherence across the United States and Europe, 
which revealed an average adherence rate of 69% for first filling of prescription, falling off to 43% 
from first filling of prescription to continuous refill after six months.3 Given the increasing prevalence 
of chronic diseases (e.g. diabetes, allergies and cardiovascular or degenerative diseases), which 
require long-term treatments, the problem of non-adherence to therapy has been identified as a 
major problem facing medical practice.
Another recent adherence survey, carried out by Booz & Company, demonstrated that non-
adherence to therapy is a common and significant problem in healthcare.10 Existing literature further 
confirms that patients find it difficult to adhere to their medication regimens when suffering from 
a number of different conditions. For example, research indicates patients with hypertension take 
only 50% to 70% of the prescribed doses of their antihypertensive medications and up to 50% 
of patients discontinue their treatment within the first year. In addition, up to 75% of patients 
do not achieve target blood pressure (BP).11 A literature review of patients on antidepressants 
demonstrated that almost half prematurely discontinued therapy within six months of initiation.12 
A meta-analysis demonstrated that medication non-adherence rates in heart failure patients 
range typically from 40% to 60%, with some studies reporting values as extreme as 10% to 
92%.13,14 Although it is well known that antidiabetic, antihypertensive, and lipid-lowering therapies 
significantly reduce the risk of ischaemic events, long-term adherence to these medications is poor 
even among patients who have already experienced a cardiovascular event.15
The Irish Platform for Patients’ Organisations, Science and Industry (IPPOSI) has identified patient 
non-compliance and non-adherence as an important issue to highlight, discuss and tackle.2 On 
June 27th, 2013, IPPOSI held a roundtable meeting entitled “A Focus on Patient Compliance & 
Adherence”.2 This roundtable identified poor medication and treatment compliance as a significant 
issue within the Irish health system, which affects patient outcomes and costs for the health service. 
Arising from the roundtable discussion, IPPOSI identified a number of key recommendations and 
consensus points. Principal amongst these recommendations was the need for a specific body 
or working group to be formed to address the issue of medication and treatment compliance in 
Ireland.2 Furthermore, there was also agreement that specific and detailed Irish research was 
needed to examine the issues behind compliance failure across preventative, chronic and acute 
treatment.2
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Non-adherence to medication can have a negative impact on the efficacy of treatments, patient well-
being and the use of healthcare resources.1,16-19 Non-adherent diabetes and heart disease patients 
have been estimated to have significantly higher mortality rates than adherent patients.16 This 
may be because medication non-adherence contributes to many patients failing to achieve targets 
e.g. those who are prescribed statins.17 One study suggests that an estimated 86,000 premature 
deaths per year could potentially be avoided among hypertensive patients in the United States, with 
appropriate and optimally used medication.18 Another study found that the risk of hospitalisation, 
rehospitalisation, and premature death among non-adherent patients is 5.4 times higher in 
hypertension, 2.8 times higher in dyslipidaemia, and 1.5 times higher in heart disease compared 
with adherent patients.19 Furthermore, the WHO report stated that poor adherence to recognised 
standards of care is the principal cause of development of complications of diabetes and their 
associated individual, societal and economic costs.1
The negative effects on outcomes are not restricted to cardiovascular or metabolic disease. An Irish 
study found that poor adherence with osteoporosis medications resulted in around a 50% reduction 
in the potential benefits observed in clinical trials and a doubling of the cost per quality-adjusted life 
year (QALY) gained from these medications.20 In addition, health-related outcomes (poor control, 
exacerbations, hospitalisations, lung function decline), associated with severe asthma, are often 
worsened by non-adherence.21 A study of HIV patients revealed adherence levels less than 95% 
independently predicted viral failure, hospital admissions and opportunistic infections.22
Costs to the healthcare system
Poor adherence is also linked to adverse patient outcomes leading to increased consumption of 
healthcare resources.1,15,24,25 Medication non-adherence is costing EU governments an estimated 
€125 billion and contributing to the premature deaths of nearly 200,000 Europeans annually.31 
In the United States, non-adherence has been estimated to cost the healthcare system between 
$100 billion and $289 billion annually.23 In a United States study of patients with heart failure, it is 
acknowledged that medication adherence rates within this population vary widely. The suboptimal 
drug use in these patients is associated with an increase in unplanned hospital admissions, increased 
mortality and morbidity rates, accompanied by additional healthcare-related costs.24 In addition, 
of all medication-related hospitalisations that occur in the United States, between one-third and 
two-thirds are the result of poor medication adherence15 and as much as a 40% increase in nursing 
home admissions.25
The direct costs of complications attributable to poor control of diabetes are 3–4 times higher than 
those of good control.1 Another study in diabetic patients found that hospitalisation rates were 
significantly lower for patients with high medication adherence.26 The UK’s National Institute for 
Clinical Excellence (NICE) produced guidelines for patient adherence in which it estimated that 
the cost of hospital admissions resulting from patients not taking medications as prescribed was 
between £36million - £196million in 2006-2007.27
According to the WHO, improving adherence to medical therapy for conditions of hypertension, 
hyperlipidaemia, and diabetes would yield very substantial health and economic benefits.1,15 
However, in order to achieve this, the causes of non-adherence must be understood. 
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Factors affecting adherence
There are a wide variety of factors which determine patients’ adherence. They can be broadly 
categorised as follows:1
•  Patient-related factors
•  Healthcare system and provider-related factors
•  Treatment-related factors
•  Condition-related factors
• Socio-economic & demographic factors
The WHO has used this classification to sub-divide the factors they identified in their report. In order 
to simplify the findings in the current Irish survey, we have also sub-divided the factors we found 
in this study in a similar fashion. However, it is very important to note that these factors represent 
overlapping issues affecting adherence.
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Men
Women
U35
25-34
35-49
50-64
65+
Middle class
Working class
Farming
Urban
Rural
25%
13%
25%
30%
10%
29%
19%
35%
25%
28%
Survey Findings2
2.1 Literature search 
The literature search identified 47 articles after applying certain selection criteria (Appendix 1).  
Both randomised and non-randomised studies were included as well as systematic reviews and 
surveys (Appendix 1).
2.2 Overview of survey findings 
2.2.1 Illness incidence
The survey demonstrated that 27% (281) of all participants (30% women and 25% of men) suffer 
from a listed condition in the questionnaire (Figure 1). 212 of 281 patients with a listed condition 
(75%) were prescribed medication by their doctor. The incidence of illness varied among the age 
groups with the highest frequency being reported in Irish adults ≥50 yrs of age. Furthermore, pa-
tients in this age group were more likely to be suffering from multiple conditions than those outside 
this age group (Table 1).
Figure 1: Incidence of illness
Do you suffer from any of the following?Q
Any listed
illness
Do not suffer  
from any listed illnesses
27%
46%
56%
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Table 1: Number of Conditions Experienced by Age
 
Elevated blood pressure and hypercholesterolemia were the most common conditions reported by 
the participants. Many people suffered from multiple conditions; 27% of 1,003 subjects suffered 
from at least one condition. Of those 27% (n=281): 17% suffered from just one condition (60%  
of 281 subjects) and 11% suffered from two or more conditions (40% of 281 subjects) (Table 1). 
Generally, a significant overlap was found between heart disease, hypercholesterolemia and blood 
pressure. Those with arthritis, asthma, infections, depression and cancer were less likely to have a 
second condition (data not shown).
Figure 2: Frequency of conditions identified (many suffered from multiple conditions)
Do you suffer from any of the following?Q
All Adults Under 35 35-49 50-64 65+
Base 1003 357 273 218 155
% % % % %
Any Condition 27 11 19 46 56
One Condition 17 8 14 27 27
Two Conditions 6 2 4 10 13
Three Conditions 3 1 1 6 11
4+ Conditions 2 – 1 3 5
Single/All 60% 73% 71% 59% 47%
Multiple/All 40% 27% 29% 41% 53%
High/low blood pressure
High cholesterol
Arthritis
Asthma
Diabetes
Heart Disease
Chronic Pain
Depression
Migraine
Psoriasis
Cancer
Osteoporosis
Other mental illness
Epilepsy
COPD
Multiple sclerosis
Drug Addiction
8%
8%
7%
4%
3%
3%
2%
2%
2%
2%
1%
1%
*
*
*
*
*
* Indicates less than 0.5% 
27% suffer with any of these conditions
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2.3 Adherence overview 
2.3.1 Overall adherence rates
The survey demonstrated that the adherence rate in all patients regardless of their condition was 
82%; 18% of the study population were non-adherent. Men were slightly less likely to be adherent 
than women. There was a tendency towards increasing adherence rate with age, with patients aged 
≤35 yrs reporting the highest rate of non-adherence at 23% (Figure 3) even though this patient 
demographic was less likely to suffer from a chronic medical condition.
Figure 3: Adherence overview for any condition (n=281)
Are you prescribed regular medication (defined prescribed  
any medication by your doctor to be taken regularly)?; Q1
Thinking about a typical month, on how many occasions if any,  
might you not fully follow your prescribed course of treatment? Q2
When adherence was examined for a specific condition, patients with heart disease and depression 
appeared to have the highest rate of adherence (93% and 91% respectively). However, the reported 
rate of non-adherence was 31% in patients with asthma, 31% in patients with diabetes and 30% in 
those with high cholesterol (Figure 4). Notably, the survey did not distinguish between type 1 and 
type 2 diabetes. 
   Always take  
medication  
without fail
   Don’t take  
it up to 5  
times/month
   Don’t take it  
more than 5  
times/month
   Not sure
All taking 
medication
212
%
Base:
Men
94
%
Women
118
%
U35
28
%
35-49
39
%
50-64
78
%
65+
67
%
ABC1
88
%
C2DE
98
%
F
26
%
3 1 4 4 3 5 4 2
6
4
3
3 4
6 2
1 4
2
3
12 19
7
15 17
12 8
12
13
10
82
76
86
77 77
83
86
79
83 81
17
93
Figure 4: Adherence overview for specific conditions (n=281)
And for which, if any of these conditions, are you on medication?;Q1
Thinking about a typical month, on how many occasions if any,  
might you not fully follow your prescribed course of treatment? Q2
When asked whether they take their medications as prescribed, 15% of those prescribed medication 
admitted to not being completely adherent to their prescription instructions at least once a month 
(Figure 5). Significantly more men generally failed to follow treatment instructions properly than 
women. 
   Always take  
medication  
without fail
   Don’t take  
it up to 5  
times/month
   Don’t take it  
more than 5  
times/month
   Not sure
All taking 
medication
212
%
Base:
Blood 
Pressure
48
%
Arthritis
31
%
Asthma
25
%
High 
Cholesterol
23
%
*Heart 
Disease
17
%
*Diabetes
19
%
*Depression
15
%
3 2 1
4
2
12
16
7
12
10
6
14
30
7
24
9
82
86
82
68 70 69
91
* Small base
18
Figure 5: Proportion of patients not fully adherent at least once a month
Thinking about a typical month, on how many occasions, if any,  
might you not fully follow your prescribed course of treatment? Q
65+
All
Men
Women
U35
35-49
50-64
ABC1
C2DE
F
Not 100% adherent at least once a month
23%
23%
15%
10%
19%
14%
9%
13%
17%
15%
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Of those patients with a medical condition on prescribed medication, 18% admitted to not taking 
their medicines as instructed. Of those who don’t always take their medication as instructed, 64% 
were missing doses at least once a week (Figure 6). 
Figure 6: Proportion of patients not fully adherent at least once a week
On how many days in a typical week might you miss taking  
your prescribed medication as instructed on average?  Q
Serious  
condition
No condition
Typically 
take meds 
as instructed 
(22%) Don’t always take my medication  
as instructed (5%)
None
One
Two
Three
4 or more
Don’t know
36%
25%
8%
7%
4%
21%
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82%
18%
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2.4 Factors affecting adherence 
2.4.1 Overview of adherence factors from the literature analysis
Factors affecting adherence identified by the literature analysis are summarised in Table 2. An 
overview of the factors identified in this survey are summarised in Table 3. Generally there was a 
high degree of concordance between factors identified in this survey and the literature analysis. 
Table 2: Adherent vs. Non-adherent Patient Characteristics from the Literature Analysis
Adherent Non-adherent
Disease related factors
•  Type of illness
•  Enlarged prostate; cancer; cardiac problems; and 
Parkinson’s disease (adherence rate ≥60%)3
•  Severe illness3,44,28
•  Higher level of disability (physical, psychological, social 
and vocational) and higher rate of disease progression3
•  Multiple disorders/comorbidities14,24,53
•  Type of illness
•  Depression; pain; bronchitis; GERD; HIV; incontinence; 
arthritis (adherence rate 50-59%)3
•  Lung condition48
•  Multiple disorders/comorbidities53
Healthcare system- and providers- (management team) related factors
•  Patient/caregiver support48 
•  Good personal connection with a doctor and/or 
pharmacist1,3,15,48,67 
•  Quality, duration and frequency of doctor/patient contact67
•  Patient satisfaction with their healthcare
• Doctor/patient poor communication & relationship1,3,15,67
•  Lack of quality, duration and frequency of doctor/patient 
contact67
•  Lack of understanding of patient needs3
•  Ineffective communication about adverse events15
•  Lack of continuity with the same provider15
•  Limited access to care (e.g. short visit times)15
•  Non-availability of medical or social support to cope  
with side effects1
•  Lack of patient satisfaction with their healthcare67
Patient related factors
•  Better information and understanding of illness29,48,61
•  Patient involvement in decision making67
•  Better communication with healthcare provider46,48,67
•  Patient satisfaction with treatment62
•  Low understanding of illness3,15
•  Lack of involvement in treatment decision15,67
•  Forgetting medication3,48
Treatment related factors
•  Good drug effectiveness and tolerability3
•  Positive perception of treatment46,62
•  Complexity of the medical regimen and frequent changes 
to treatment1,3,51,53
•  Duration of treatment and previous treatment failure1,3,63
•  Poor drug effectiveness and/or tolerability3,44,51,65
•  Perceptions of diagnosis and health risks associated with 
disease and treatment1,3,46,48
•  Cannot remember why medication is needed1,11,68,62
•  Route of administration3
Cost-related factors
•  Afford medication3,48 •  Cannot afford medication3,48,51
Socio-economic factors
•  Older age48,53 
•  Female patients61,63
•  Younger age48 
•  Male patients61,63
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2.4.2 Characteristics of adherent/non-adherent groups from the survey
Table 3 outlines the characteristics of adherent vs. non-adherent patients as identified in this survey. 
Table 3: Adherent vs. Non-adherent Patient Characteristics from the Survey
2.4.3 Condition-related factors
Approximately 60% of 281 patients with a condition in the survey suffered from at least one condition 
and over 40% suffered from two conditions or more (Table 1). The likelihood of suffering from more 
than one condition increased with age; in fact 53% of subjects ≥65 yrs reported suffering from 
multiple conditions (Table 1). The survey data demonstrated that adherence correlates negatively 
with increasing number of conditions, 59% of those with one condition claim to take their medication 
without fail dropping to only 15% in those with three conditions (data not shown). 
 
Adherent Non-adherent
Disease related factors
•  Single condition
•  Those with heart disease, depression or blood pressure, 
psoriasis, and migraine
•  Multiple conditions
•  Those with arthritis, hypercholesterolaemia, asthma, and 
diabetes; long-term blood pressure
Healthcare system- and providers- (management team) related factors
•  Recent medicine review with the doctor
•  Talk regularly to the doctor
•  Long lead times between reviews with doctor
•  Talk regularly to pharmacist
Patient related factors
•  Better understanding of illness
•  Using a reminder/prompt
•  Poor understanding of illness
•  Not using a reminder/prompt
•  Worry about illness getting worse
Treatment related factors
•  Confident about their medication •  Don’t feel better with medication
•  Concerns regarding side effects
•  Medicine doesn’t address symptoms adequately
•  Cannot remember why medication is needed
Cost-related factors
•  Medical card •  Private patients
•  Healthcare schemes
Socio-economic factors
•  Female, less affluent, more likely to have a family support 
structure
•  Older age
•  Male, affluent, lack of conventional family support 
structure
•  Younger age
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2.4.4 Healthcare system and provider-related factors
2.4.4.1 Frequency of involvement with healthcare professionals and adherence
Figure 7a illustrates recent review dates of patients with their respective healthcare professionals. 
Approximately 43% of patients had a review with a healthcare professional in the past month. More 
recent reviews were more likely for patients on medical cards vs. those who were self-funded or on 
other healthcare schemes (59% vs. 38% and 43% respectively) (Figure 7a). 
Chronic pain was the most frequently reviewed condition by doctors (Figure 7b). Patients with 
conditions such as high cholesterol, asthma or migraine were notably less likely to have had a recent 
review with their doctor (Figure 7b). 
Figure 7a: Latest review/discussion of any condition with doctor
When did you last discuss/review your condition with your doctor?Q
  Past week
   Past month
   Past 3 months
   Past 6 months
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Patients who were reviewed by healthcare professionals within the last month tended to be more 
adherent to their treatment than patients who had longer time intervals between reviews (Figure 8). 
Figure 8: Recent review/discussion of condition with doctor and adherence (for any condition) 
When did you last discuss/review your condition with your doctor?Q
Figure 7b: Latest review/discussion of specific conditions with doctor
Any Condition
Chronic pain
Diabetes
Heart Disease
Asthma
Depression
Arthritis
Blood Pressure
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Past month
%
Past week
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2.4.4.2 Management strategies/patient review/follow-ups/check ups 
The patients surveyed on regular medication provided their view of the extent of contribution  
of various factors to the perceived effectiveness of the treatment of their condition. The results  
are demonstrated in Figure 9. Regular check-ups and advice from the doctor scored highest  
whereas advice from pharmacists scored lower in terms of factors affecting perceived  
effectiveness of treatment.
Figure 9: Factors affecting patients’ perceived effectiveness of treatment of their condition 
How well or badly do you feel the following aspects help you to treat your condition? Q
Advice from pharmacist (3.88)
FACTOR (SCORE)
Pr
op
or
ti
on
 o
f 
pa
ti
en
ts
Medication (4.12)
Advice from the doctor (4.23)
Blood Test (4.10)
Regular tests and check-ups (4.22)
0% 10% 20% 30% 40% 50%
Percentage represents percentage of patients scoring these factors a score of 1-5. 
29%
35%
40%
42%
43%
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2.4.4.3 A view of patient adherence by carers 
A total of 7% of the subjects surveyed were also carers, mainly for elderly relatives. Additional 
questions were asked of the carers regarding their attitudes towards the individuals in their care.
The majority of carers (75%) reported that the person they care for was on a complex treatment 
regimen. 
52% of carers claimed that the person they care for regularly forgets to take all their medication. 
39% admitted that their patients are good at taking their medication regularly and 57% stated that 
the patients they care for have a tool to help them remember their medicines. 42% of the carers felt 
the person they care for does not fully understand their medication regimen (Figure 10).
Figure 10: Attitude of carers 
To what extent do the following apply in relation to the person you care for?Q
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   Agree slightly
   Does not really apply
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2.4.5 Patient-related factors
2.4.5.1 Patient-reported factors affecting adherence 
Patient-reported barriers to adherence are shown in Figure 11. 
Amongst non-adherent patients, 29% reported that not remembering to take medication is a barrier 
to adherence. The most commonly reported barrier to adherence was the perception that taking 
their medication didn’t make them feel any better or worse (44%) and the perception that their 
treatment will not prevent further deterioration of their condition (39%) (Figure 11).
Figure 11: Patient-reported barriers to adherence among non-adherent patients
Thinking about occasions where you may not fully comply with your prescription,  
to what extent do the following factors apply to you personally?Q
  Agree strongly
   Agree slightly
   Does not really apply
   Does not apply at all
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2.4.5.2 Patient reasons for missing medication 
The most commonly reported reason for missing medications was simple forgetfulness (71% of 
all respondents). Other reasons included patient perception that they don’t need the medication 
anymore (20%); they felt better (16%); they were anxious about the side effects (5%) or they 
didn’t believe that the medication was effective (4%) (Figure 12). 
Figure 12: Patient reasons for missing their medication 
What causes you not to take your medication for ………….? Q
I forgot
I don’t really think I need it
I feel better, don’t need to anymore
I am anxious about the side effects
I don’t think it works
71%
20%
16%
5%
4%
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2.4.5.3 Patient factors promoting adherence 
Factors promoting adherence are summarised in Figure 13. The three factors ranked most important 
in ensuring people take their medication were talking regularly to the doctor (74%); having a good 
understanding of the illness (42%); having a good understanding of the medication (40%). In 
addition, talking regularly to their pharmacists and having a routine to help them remember to take 
their medication were also considered important. Worrying about deterioration of the illness was 
among the lowest rated factors (Figure 13).
Figure 13: Patient-rated factors affecting adherence
Which of the following factors are important in ensuring your  
own continuation with your medication as prescribed?Q
I talk regularly to my doctor
I have a good understanding 
of my illness
I have a good understanding 
of my medication
Medicines are important
I have a routine so I do not forget 
to take my prescribed medication
I feel better when I take 
my medicine
I talk regularly to my pharmacist
It improves/reduces symptoms 
or conditions
I am worried about my illness 
getting worse
Other factors
74%
42%
40%
40%
39%
38%
37%
17%
19%
2%
29
Patient-related factors which were considered important in improving adherence are shown below in 
Figure 14. Both adherent and non-adherent patients agreed that the importance of understanding 
their illness, understanding how their medication works and being able to discuss concerns about 
medication with their doctor/pharmacist were important in helping support adherence. 
Figure 14: Importance of patient factors for promoting adherence 
How important are the following factors for improving their disease getting better?Q
  Very important (4)
  Quite important (3)
   Not that important (2)
   Not at all important (1)
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2.4.6 Treatment-related factors
2.4.6.1. Effectiveness of medication 
Almost 35% of all patients perceived their medication as very effective or that it treats their 
condition excellently and overall, 80% claimed that that their medication treats their condition 
excellently or very well (Figure 15). 
Figure 15: Perceived effectiveness of medication by the patients 
How well do you feel that your medication treats your condition(s)?Q
  Excellently (5)
   Very well (4)
   Quite well (3)
   Not that well (2)
   Badly overall (1)
17 } Lower
%
31
2.4.7 Cost-related factors
2.4.7.1 Treatment funding 
Patients with medical cards reported higher adherence rates than those self-funding or co-paying 
through various healthcare schemes (Figure 16).
Figure 16: Effect of treatment funding on adherence 
How are your medicines paid for?Q
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  I pay myself
  I get some refund through insurance
  I get them through the hospital
  I am on a Long Term Illness scheme
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I pay myself 24%
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I get them through the hospital 1%
I am on a Long Term Illness scheme 4%
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2.4.8 Socio-demographic factors
2.4.8.1 Effect of patient demographics 
A greater proportion of those surveyed who reported having a significant illness were women (Figure 
17). Of those in the sub-group with significant illnesses, more men than women were non-adherent 
(59% men vs. 41% women). Adherence generally seemed to increase with age (with a slight dip in 
the above 65 yrs age group).
Married patients were almost twice as likely to be adherent to their treatment compared with single 
patients. 
Figure 17: Effect of patient demographics on adherence
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2.4.9 Interventions to improve adherence
2.4.9.1 Results from the literature search 
Appendix 2 summarises intervention tools identified from the literature analysis. Intervention tools 
most commonly employed, which improved adherence included improving patient education about 
the disease/treatment through digital means (e-channels), patient literature or simple discussions 
with the patient; monitoring patient adherence; using reminders; simplifying medication regimens  
or employing more convenient care methods. 
2.4.9.2 Survey-reported interventions to improve adherence 
76% of participants claimed to have no method to help monitor the usage of their medications. 
Of the 24% of patients who did use an intervention/assistance method to help remember their 
medication; most used a pillbox (20%). Another specific intervention described was pharmacist-
assisted packaging of medications. Self-payers, patients ≤50 yrs and those with low compliance 
were less likely to use any self-help method (Figure 18).
Figure 18: Characteristics of patients who use interventions to assist in adherence 
Do you have any method to help you monitor usage of your medications? Q
  No
  Yes – a pillbox
   Yes – a system whereby a pharmacist 
packs a days medicine for me
  Other
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Adherence is a multidimensional phenomenon determined by the relationship of five factors or 
dimensions.1 These five dimensions have been identified within the WHO’s multidimensional 
adherence model, which incorporate socio-economic-, healthcare system-, condition-, treatment-, 
and patient-related factors.1
In this survey we have analysed:
•  Overall adherence in a sample of 1,003 adults, of which 27% (281) reported having  
a medical condition
•  Factors which affect non-adherence and adherence, sub-divided in the five sub-categories  
defined by the WHO
•  Patient behaviour
•  Interventions aiding adherence
Overall 18% of participants reported that they are not fully adherent all of the time with the number 
rising to 23% in men only; 23% in ≤35 yrs individuals; 30% in people with high cholesterol; and 
31% in people with asthma and diabetes. Various reported studies, as well as the rate reported by 
the WHO, ranges between 20-66%. 
A review of the adherence findings from literature analysis is summarised in Appendix 3.
3.1 Factors affecting adherence
Factors affecting adherence were identified through this survey and additional factors were also 
identified via the literature analysis. These are briefly discussed below.
3.1.1 Condition-related factors 
In the survey, those who were non-adherent were much more likely to have overlapping conditions. 
Of those who were generally adherent, most had a single condition; therefore multiple conditions 
may lead to increased likelihood of non-adherence. Comorbid conditions have been linked to non-
adherence in the literature also. For example, Corotto et al demonstrated comorbidities as a factor 
contributing to non-adherence in patients with heart failure.14 Similar findings have been recently 
reported for patients with liver cancer and atrial fibrillation.24
Generally multiple conditions are associated with older age, which is another key predictor of 
non-adherence. A study investigating improvement of adherence on patients ≥70 yrs of age with 
multiple conditions concluded that management of polypharmacy and reducing healthcare costs are 
important considerations when trying to improve compliance in this patient population.30 However, in 
this survey, younger age groups were slightly less adherent than older age groups. This is discussed 
further below under the “demographics” section.
Condition-related factors most likely to result in non-adherence included conditions such as high 
cholesterol and arthritis. Patients’ condition did have an effect on the level of adherence. Conditions 
with decreasing adherence, in order of highest to lowest, were; heart disease, depression, blood 
pressure, arthritis, high cholesterol, diabetes and asthma.
Discussion3
35
3.1.2 Patient-related factors 
In this survey, the most common patient-related factor leading to missing medications was simple 
forgetfulness. This is in line with the WHO finding in their adherence report.1 This finding probably 
demonstrates the role for medication reminder prompts for all patients. 
The survey also demonstrated that frequent engagements with the doctor together with a good 
understanding of the illness and the medication prescribed were amongst the highest-rated patient 
factors promoting adherence; even more so than any concerns over deterioration of the illness. 
This was further demonstrated in the literature analysis with a significant number of publications 
advocating the value of patient education (Appendix 2). The Capgemini survey emphasised that the 
patients who lack understanding of their condition, of why they need this medicine or intervention 
and why they would benefit from the medicine tend to have poor adherence.3 Furthermore, the 
doctors’ lack of ability/time to convey the importance of the above was one of the biggest drivers for 
non-adherence.3 Lack of emphasis on treatment education and adherence by doctors is viewed as 
one of the most critical of these patient factors influencing adherence.
In a European Policymakers debate convened in 2010 to discuss medication non-adherence, it 
was emphasised that patients’ understanding and belief in the information provided about their 
medication is a critical factor in improving adherence, as this improved patients’ confidence in using 
the treatment.31 A National Community Pharmacists Association (NCPA) survey in the United States 
concluded that better information, communication and patient/caregiver support increase patients’ 
engagement and involvement in their healthcare, their satisfaction with their care and their loyalty 
to their healthcare providers.32
Interestingly, in a rheumatoid arthritis study of 108 patients, the data demonstrated that medication 
adherence and illness perception were not improved by use of multimedia or patient literature within 
one month.33 This may be specific to arthritis patients as this survey also confirms the low adherence 
rates amongst these patients (53%); or it may be that longer lasting education programmes are 
needed for this particular patient group. The latter may be true due to the rapid developments in 
understanding of the mechanism of this disease amongst healthcare professionals and launch of 
multiple new medications (e.g. biologics) targeting various elements of the condition, necessitating 
continuous patient education. 
3.1.3 Healthcare system- and providers-related factors 
This study demonstrated that patients (even the adherent ones) benefit from regular engagement 
with their healthcare professionals, where the need and benefits of their prescribed medication 
can be explained fully (and repeatedly). This may potentially be an avenue where nurses and 
pharmacists can play a more active role.
Reviewing the condition with the doctors and frequency of reviews significantly impacts adherence. 
Patients who were reviewed by doctors regularly tended to be more adherent to their treatment 
than patients who had longer time gaps between reviews. The same applied for patients who were 
being continually monitored through check-ups, blood tests, medication monitoring, etc. Scheduling 
regular check-ups was also identified as an important factor in the IPPOSI report, which suggested 
that undertaking regular monitoring (e.g. simple blood tests) to monitor their condition may improve 
treatment compliance.2
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The data suggests another avenue to explore for improving adherence, namely reviewing and 
monitoring adherence. Literature analysis provided further collaboration that regular patient  
review and monitoring does indeed tend to influence adherence positively (Appendix 2) and 
monitoring tools may be useful to explore as interventions for improving adherence. For example, 
Corotto et al have recently demonstrated improvements in adherence levels with telemonitoring in 
heart failure patients.14
A total of 7% of the subjects surveyed were also carers, mainly for elderly relatives. The majority 
of these carers (75%) felt that the person they care for is on a complex treatment regimen. Not 
only are complex regimens difficult to remember, they can often translate into high medication costs 
for patients, another factor which may affect adherence. Once again, this finding was supported 
by the literature analysis (Appendix 2). Complex medication regimens are discussed further under 
“treatment-related factors” section below. 
3.1.4 Socio-demographic factors 
Patient demographics affecting adherence negatively include male sex and younger age (under 50 
yrs). Married subjects tended to have a better adherence profile than single subjects. This may be 
due to the family support structure affecting adherence. In general, more men than women were 
found to be non-adherent. 
The WHO states older age as a factor affecting adherence.1 In this survey, adherence generally 
seemed to increase with age (with a slight dip in the above 65 yrs age group). In the literature 
analysis, race and sex have not been consistently associated with levels of adherence; however, race 
was not evaluated in this survey.
The NCPA survey, in the United States, also found that older Americans indicate greater adherence 
than younger respondents, similar to this survey but again different from WHO findings.32 So, the 
reason for the discrepancy may also be that the WHO findings were reported in 2003 and the NCPA 
findings in 2010 (this survey was undertaken in 2013) and the pattern of adherence has probably 
changed across the various age groups, but larger studies are needed to verify this. 
The lack of adherence reported amongst younger age groups (<49 yrs) is a concern. Treatment 
adherence (including prescribed medication) matters for the working-age population, given the onset 
of many chronic diseases early in life and the fact that people are retiring later in life. Treatment 
can help prolong productivity in this population and adherence to medicines will improve long-term 
outcomes. It may be that younger individuals, who are generally more likely to consult the internet 
to understand their condition and medications, need more time with the healthcare professional to 
fully discuss their condition and be convinced of the benefits of adhering to their regimen. This can 
be achieved by gaining their confidence during longer consultations and regular follow-up.  
3.1.5 Treatment-related factors 
Complex medication regimen was identified as a key factor influencing adherence. This was also 
reported by almost all the publications analysed (Appendix 2). Complex medical regimens tend to 
confuse patients and simpler formulations were generally preferred by participants in this survey. 
Novel and simpler drug formulations (e.g. fixed dose combinations) can help tackle this issue. 
Indeed, many studies have emphasised that interventions which reduce the dosing demands of 
individual therapies can improve adherence.1,3,5,6,7,15
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This survey also found that patients tend to doubt value of their medication over a long period 
of time, which can be a concern in chronic illness. These findings are also consistent with the 
literature analysis. Generally, patients cannot see visible recovery signs and hence lose faith in their 
treatment. Development of a regular communication plan, including motivational interviewing, is 
imperative in patients with chronic disease to keep them motivated. 
Addressing medication-related factors will require better communication between the patient 
and his/her prescriber about what to expect from treatment and dosing regimens.34 Through 
high-quality, two-way discussions, doctors will be able to identify and discontinue unnecessary 
medications, simplify dosing regimens, and address other medication-related issues that make 
adherence difficult.34 Pharmacists have also an important role to play here.
In the Capgemini survey, respondents rated patient- and therapy-related factors among the top 
factors driving adherence.3
3.2 Improving adherence
This survey indicates that healthcare professionals, especially the patients’ doctors, are key 
influencers towards improving patient adherence. This is in agreement with previous findings. 
However, other stakeholders, such as pharmacists, also have an important role to play in improving 
patient adherence (e.g. through smart dispensing, counselling, education, etc). Indeed, in type 2 
diabetes, pharmacist interventions may improve medication adherence by 15 to 20%.10
Improving adherence can be difficult, but the literature analysis has identified some approaches, 
which helped improve adherence (Appendix 2). Moreover, these strategies can help save costs for 
the healthcare system overall and hence present a good investment for policymakers. 
Haynes et al conducted a Cochrane review, where they concluded that outcomes of interventions to 
improve therapy adherence are mixed.35 However, they also stated that the results vary depending 
upon the conditions, the patient populations and the type of interventions.35 The review demonstrated 
that for short-term treatments, several quite simple interventions increased adherence and improved 
patient outcomes, but the effects were inconsistent from study to study with less than half of studies 
showing benefits. The review further concluded that current methods of improving adherence for 
chronic health problems are mostly complex and not very effective, so that the full benefits of 
treatment cannot be realised. Although this review discussed innovations to assist patients to follow 
medication prescriptions for long-term disorders, one must also consider the fact that interventions 
may have to be personalised to demonstrate a significant effect in improving adherence.35
This is precisely what this survey is showing here. Interventions to improve adherence have to be 
specified according to the type of disease, patient population, healthcare provider, etc. For example, 
regular healthcare provider counselling may be a beneficial intervention in certain chronic diseases 
such as arthritis but other diseases may require a different type of intervention. Therefore, the 
intervention has to be individualised to the patient’s needs.  
Appendix 2 summarises some intervention methods identified through the literature analysis that 
have shown benefits in various therapy areas. Through promoting such approaches and creating 
incentives and rewards for providers for undertaking these interventions, treatment adherence can 
be improved and providers can further develop innovative interventions specific to their patients to 
further improve outcomes and reduce long-term care costs. Some examples of such interventions 
are highlighted below.
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Patient education plays a central role in improving adherence as seen in this survey and the 
literature analysis (Appendix 2). The WHO report specifically called on health professionals, 
researchers, health planners and policymakers to implement a multidisciplinary approach to 
adherence education and management, emphasising the value of patient education.1
Patients who have difficulty maintaining adequate adherence need more intensive strategies than 
patients who have less difficulty with adherence, a more simple medication regimen, or both.36 New 
technologies such as reminders through text messages and personal digital assistants and pillboxes 
with paging systems may be needed to help patients who have the most difficulty meeting the 
goals of a regimen.3,36 These tools may prove very useful moving forward as forgetfulness was cited 
as the single most frequent cause of non-adherence in this survey and in the literature analysed. 
Innovative approaches can include reducing complex medical regimens and smart dispensing of 
medications. O’Carroll et al demonstrated that using an electronic pill dispenser improved adherence 
rates by 10% in stroke survivors.37 Other approaches to improve medication regimens include 
development of longer-lasting formulations. Indeed, there is extensive evidence of the benefits of 
longer-lasting formulations on patient adherence (Appendix 2).
Successful behavioural interventions based on monitoring, regular visits and feedback have also 
demonstrated better outcomes for patient adherence.3,7,14 In a study of tuberculosis patients in 
the United States, Chang et al demonstrated that monthly home-based follow-up was an effective 
method of increasing adherence.38 Home-based follow-up included language translation, medication 
delivery, assessment of compliance with pill counts, monitoring for adverse effects, and active 
tracking of non-compliant patients.38 Similarly, a review recently emphasised the importance of 
home blood pressure measurements for improving assessment and adherence to medications.39 
Customer call centres in clinics, in addition to helping patients with queries, can serve to monitor 
adherence.3 In a heart failure patients’ study, compliance with a daily telemonitoring protocol 
was shown to be 98.5% over six months, and there was a 56% reduction in mortality in patients 
randomised to the telemonitoring group (p<.003). Thus, this study illustrated the potential of 
telemonitoring systems to vastly improve adherence.14,40
Patient Education
The WHO states that good adherence education may be based on:1
•  Stressing the importance of adherence at the time the therapy is initiated
•  Emphasising the consequences of non-adherence
•  Spending adequate time with the patient
•  Enquiring about adherence at each visit
•  Motivating patients to incorporate medication adherence into their lifestyles and
•  Designing and implementing intervention strategies to improve adherence to self-medication
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Although 20% of patients surveyed in this study used pillboxes to assist them in remembering 
their medications, this was not a very common finding in the literature analysis. In a trial of 
hypertensive patients in France, compliance was measured using electronic pillboxes equipped with 
a microprocessor that recorded date and time of each opening (Medication Event Monitoring System 
[MEMS]). The compliance rate was 98.9% in these patients, though the study did not have an arm 
without the pillbox.41 A study comparing electronic or normal pillboxes vs. no intervention may be 
warranted based on these data.
In some patients, counselling or cognitive behavioural therapy may be needed, especially for 
patients with chronic conditions such as arthritis or diabetes. For example, a recent study of 87 
patients demonstrated significant benefits of cognitive behavioural therapy on adherence as well  
as patient outcomes in type 2 diabetes patients with depression.23,42
Al-Eidan et al (2002) demonstrated that offering counselling from a hospital pharmacist and a 
follow-up phone call after three days of antibiotic therapy (including mentioning possible side-
effects) resulted in significant improvements in adherence (measured using pill count) and patient 
outcome.43 The control population in this study received a standard letter explaining the nature of 
the infection and the need for treatment. They were asked to contact their general practitioner (GP) 
to obtain the necessary prescription. The study demonstrated the value of patient counselling since 
the intervention group were significantly more compliant than those in the control group.43
There is some evidence to suggest that self-management programmes offered to patients with 
chronic diseases improve health status and reduce healthcare resource utilisation and costs.1 A 
self-management programme based on feedback of adherence performance and principles of 
social cognitive theory has shown improvements in adherence to antiretroviral dosing schedules in 
HIV patients.44 The National Kidney Foundation’s “Clinical Practice Guidelines and Clinical Practice 
Recommendations for Diabetes and Chronic Kidney Disease” states that there is some evidence 
that self-management approaches based in behavioural medicine may be effective in enhancing 
adherence to the management regimen for diabetes and chronic kidney disease.45 In asthmatic 
patients treated with inhaled corticosteroids, education and training in self-management improved 
adherence with inhaled therapy.46
To improve patient adherence, increased collaboration between healthcare stakeholders is vital.3 
A collaborative approach to care augments adherence. Typical stakeholders who would share an 
interest in improving adherence include employers, payers, healthcare delivery systems, and public 
sector programme managers. Organisational strategies to improve adherence include: improving 
patient access, provider training and support, incentives, patient education and healthcare 
technologies. 
Technological advances also allow smart interaction with patients, and include pill calendars, use of 
text messages, e-monitoring service, etc. Mobile applications provide a useful medium for educating 
patients about diseases and treatments.47 Furthermore, these applications can help doctors stay 
connected to patients to monitor their progress and adherence. Indeed, a study in HIV patients, 
which reviewed the literature on the use of mobile technology for HIV/AIDS, revealed evidence that 
mobile health tools support adherence to antiretroviral treatment.48
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This new survey and the literature analysis conducted demonstrated a clear need for developing 
and implementing evidence-based interventions for improving medication adherence, providing 
better training and guidance for all healthcare providers so they can deliver effective adherence 
interventions.49 Payers can lead these projects with support from other associated stakeholders. 
In the UK, NHS reforms promise better health outcomes and improved adherence levels through 
building a patient-centric healthcare system using collaborations from various disciplines.3
Electronic health records (EHR) will be a key component in building an integrated healthcare IT 
framework.3,50 Digitisation of patient records will also help improve adherence.3 Digitisation will 
help identify causes and consequences of adherence and through sharing this information amongst 
relevant stakeholders, non-adherence could be better managed and programmes developed to 
promote adherence. EHRs can further help providers in supporting clinical decisions, payers in 
constructing accurate pay for performance models, and patients themselves in monitoring their 
treatment and progress.3 EHRs are already being used in the United States in the management of 
chronic conditions such as coronary heart disease to monitor adherence though their usefulness still 
remains to be determined.51
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Conclusions and Future Outlook4
Adherence can lead to a decrease in prescription medication costs as well as a decrease in 
complications resulting from not taking the medications as instructed. Non-adherence can be 
viewed as behavioural in origin – best treated by identifying individual risk factors and designing 
targeted interventions.28 Non-adherence is common, contributing to substantial morbidity, mortality, 
and increased healthcare costs. Interventions that target adherence must be tailored to particular 
illness-related demands experienced by the patient3 e.g. additional psychological counselling for 
patients with pain-related conditions. To accomplish this, healthcare providers must assess factors 
that influence adherence as well as adherence itself.
We report here results of a recent Irish survey examining medication adherence in multiple chronic 
conditions. The survey data demonstrated that adherence to prescribed medication remains an 
issue in Ireland with non-adherence rates varying between 23% and 31%, depending on various 
demographic factors and/or the medical condition in question. The survey data suggest that there 
may be a need for personalised interventions to overcome non-adherence.
Healthcare providers can have a significant impact by assessing the risks of non-adherence 
and delivering interventions to optimise adherence.1 To make this practice a reality, healthcare 
professionals must have access to specific training in adherence management, and the systems in 
which they work must be designed to support this objective. Their training should ideally address 
three topics: knowledge (information on adherence), thinking (the clinical decision-making process) 
and action (behavioural tools for health professionals to monitor and encourage adherence).1 
Policymakers can further provide incentives for providers to better manage adherence.
Collaboration needs to be built into patient adherence strategies. Future research should consider 
interventions that have been successful in various therapy areas and those involving partnerships 
between patients, clinicians, pharmacists and other relevant stakeholders.
There is a lack of national or international policies or guidelines addressing the problem of non-
adherence. There is a need to produce evidence-based recommendations for policymakers in order 
to help healthcare services improve patient adherence.
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APPENDICES
APPENDIX 1: Survey methodology and literature analysis 
Survey rationale 
Poor adherence results in adverse health outcomes, requiring utilisation of more expensive 
healthcare resources. There is a paucity of data on non-adherence and its impact in Ireland. This 
survey was undertaken in order to analyse patient adherence in Ireland and examine adherence 
factors which hinder/promote it. 
Survey consultation and assimilation 
The research was conducted by Behaviour & Attitudes Ltd. The study involved a quantitative phase 
of research, incorporating interviews with a nationally representative sample of 1,003 adults aged 
16 yrs and over, of whom 283 reported suffering from one of a number of significant conditions. The 
objective was to gain an insight into adherence with prescribed medication in general. The survey 
focused on habits and behaviours as opposed to specific issues with specific treatments. 
The contact sample of 1,003 was quota-controlled with targets per interviewer set so that the 
ultimate sample design mirrored the adult population structure in respect of gender, age, social 
class, region and area of residence. Interviewing was undertaken face-to-face and in-home with 
respondents screened for eligibility based upon their satisfaction of each interviewer’s quota targets. 
Only one respondent per household was interviewed. The interview was administered by a trained 
and supervised member of Behaviour & Attitudes interviewer panel. Fieldwork was undertaken in 
May/June 2013.
Literature analysis 
A review of published literature (papers published within the last ten years) was carried out to 
examine patient adherence to supplement the survey data. The literature search terms included 
various combinations of the following words: adherence and/or compliance +/- long-term treatment 
use and/or chronic conditions and/or patient and/or healthcare costs or factors or strategies/
improving. The literature review was further supplemented with adherence reports from various 
sources such as Booz & Company, Capgemini report, WHO 2003 report, National Community 
Pharmacists Association (USA) Report 2013, the ABC Report and the Irish Platform for Patients’ 
Organisations, Science and Industry Adherence (IPPOSI) Roundtable Report 2013. 
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Results of the literature analysis
Study Number of subjects/studies Country Conditions investigated
Al-Eidan FA 200243 76 patients UK Dyspepsia
AlGhurair, 201211 1,712 articles Multiple Hypertension
Aloia MS 201352 227 patients USA Sleep apnoea 
Andrejak M 200041 162 patients France Hypertension
Bartlett D, 201353 206 patients Australia Sleep apnoea 
Bermingham M, 201117 119 patients Ireland Hypercholestaerolemia
Bitton A 201354 25 articles Multiple Coronary artery disease
Bourdin 201221 Multiple Asthma
Bryant 201355 7 studies Multiple Chronic obstructive  
pulmonary disease (COPD)
Canas 20125 n/a Europe Schizophrenia
Catalani C 201348 62 studies USA HIV/AIDS
Chang 201338 3,918 patients USA Tuberculosis
Christensen 200956 62 studies Multiple Hypertension
Clyne 201249 50 stakeholders 14 countries Multiple
Danford CP 201351 3,779 patients USA Coronary artery disease
Duff AJ 201357 60 physicians UK Cystic fibrosis
Fuangchan A 201358 16 studies Multiple Malaria
Goldberg LR 200340 280 patients USA Heart failure
Hauber AB 200959 407 patients USA & UK Type 2 diabetes
Haynes 2008 (Cochrane)35 65 articles Multiple Multiple
Higashi K 201360 37 studies Multiple Schizophrenia
Janson SL 200346 65 patients USA Asthma 
NCPA Report32 1,020 subjects USA Multiple
Kang MG 201361 475 patients Korea Asthma 
Kripalani S, 20077 37 studies Multiple Chronic medical conditions
Kucukarslan SN. 201262 11 studies Multiple Multiple
Laba TL 201363 18 patients Australia Osteoarthritis
Li J, 201364 183 patients China Epilepsy
Mallick R 201329 1,127 patients USA Hepatocellular carcinoma
McDonald HP 200242 34 studies Multiple Multiple
Nglazi MD 201365 Study in progress Multiple Tuberculosis
O'Carroll RE 201337 62 subjects UK Stroke 
Paterson et al 200022 99 subjects USA HIV
REACH* registry66 25,737 subjects Multiple Atherothrombotic disease
Safren 201367 87 patients USA Diabetes
Smith SR 200344 43 patients USA HIV/AIDS
Szymczyk I 201368 134 patients Poland Cardiovascular risk
Thorneloe RJ 201269 29 studies Multiple Psoriasis
Thunander SA 201270 4,875 patients Sweden Multiple
Unk JA 201333 108 patients USA Rheumatoid arthritis (RA) patients
Verbrugghe M 201371 25 studies Multiple Cancer
Viswanathan M 201223 4,124 studies Multiple Multiple
Vittorino GA, et al 201372 169,375 patients Italy Type 2 diabetes
Reviews and other reports identified included the ABC Report73; Booz Survey10; Boulet 20124; Capgemini survey3
*REACH: Reduction of Atherothrombosis for Continued Health
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APPENDIX 2: Interventions to improve adherence as identified  
by the literature analysis 
Interventions to improve adherence as identified by the literature analysis
Intervention
Intervention Tools
Monitoring patient adherence2,4,6,7,42,48,56,51 
•  Electronic medication delivery devices55
•  Telemonitoring/self-monitoring3,14,35,40
Use of patient reminders and monitoring devices6,17,35,42,64 
•  Reminder emails or text messages3,65
•  Tracking cards64
Pharmacist programmes3,43,55
Collaboration with patient organisations3
Treatment-related initiatives
 Simplifying dosing regimen (e.g. fixed dose formulations use), re-formulation and route of delivery of the medication  
if possible1,3,5,6,7,15,35,37,42,57,72
Improved packaging of medication or pillboxes3,41,58
Long acting medication3
Patient-related initiatives
Assessing health literacy15
Patient-specific education (e.g. counselling sessions; patient materials; websites; etc)3,4,5,6,7,15,17,23,35,42,52,53,55,58,64,67
Self-management programmes1,7,55,44,46
Addressing patient fears, misconceptions and concerns over side effects2,4
Developing a shared decision process3,4,27
Improved communication with psychologists or physicians6,7,15
Motivational interviewing of patients52,57
Cost-related initiatives
Providing discounts/vouchers3
 Copayments and improved prescription drug coverage23
Management team-related initiatives
Supportive care e.g. nurse educators3,35
Ensuring continuity of care and regular follow-ups/reinforcement of adherence benefits5,35
Educating and involving family members/carers in decision-making process5,42
Enhance e-channels so providers can share patient information, promoting collaboration to improve adherence  
e.g. health websites3
Employ “payment by results” initiatives3
Training healthcare professionals to educate patients/motivational interviewing/etc51
Counselling/family therapy35
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APPENDIX 3: Adherence findings from literature analysis 
Adherence findings from literature analysis
Report Country Condition Findings
Bermingham M,  
et al 201117
Ireland Hypercholesterolaemia •  48.7% were not fully adherent to medication 
•  Patients’ beliefs about medicines were a significant 
predictor of self-reported adherence 
Booz Survey10 U.K., Germany,  
the Netherlands
All •  20-30% patients don’t follow medical 
recommendations
Bourdin A 201221 Multiple Asthma •  50% of asthma patients are considered poorly 
adherent to therapeutic advices
Change AH 
201338
USA Tuberculosis •  More patients followed with house calls completed 
treatment (90% home vs. 73.2% clinic)
•  Patients followed at home were 21% more likely  
to complete therapy (p<0.001)
Desai & 
Choudhry 201374
Multiple Coronary artery disease •  ≤50% of patients with coronary artery disease 
adhere to their prescribed therapies
Kang MG 201349 Korea Asthma •  62.6% discontinue medication
Mallick R 201329 USA Hepatocellular Carcinoma •  21.1-28% of patients were non-adherent
NCPIE 200734 USA All •  In developed countries, adherence among patients 
with chronic conditions averages only 50%
•  49% of respondents forgot a prescribed medicine
•  31% of respondents had not filled their prescription 
•  29% of respondents had stopped taking a medicine 
before the supply finished
•  24% of respondents had taken less than the 
recommended dose
NCPA 201332 USA All •  24% completely adherent (≥60 yrs)
REACH* 
registry66
Multiple Atherothrombotic disease •  48.6% of patients were adherent
•  Adherent patients were younger, white, and had less 
severe disease
Safren SA 201367 USA Diabetes •  Cognitive behavioural therapy was an effective 
intervention for adherence in adults with type 2 
diabetes and depression
Thorneloe RJ 
201369
Multiple Psoriasis •  21.6-66.6% of patients were adherent  
(33.4-78.4% non-adherent)
Thunander SA 
201270
Sweden Multiple •  66.4% were non-adherent
WHO 20031 Multiple HIV and AIDS •  Adherence varies between 37% and 83% depending 
on the drug and demographic characteristics of 
patient populations
Australia Asthma •  43% of asthma patients take their medication  
as prescribed
•  28% use prescribed preventive medication
China,  
the Gambia  
and Seychelles
Hypertension •  43%, 27% and 26%, in China, the Gambia 
and Seychelles respectively, of patients with 
hypertension adhere to their antihypertensive 
medication regimen
Multiple All •  50% adherence reported in developed countries
*REACH: Reduction of Atherothrombosis for Continued Health
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